Caution Urged as Alzheimer’s Drugs Show Risks in Cognitive Decline Treatment

Date:

Scientists have raised concerns over drugs hailed as potential game-changers in Alzheimer’s disease treatment, cautioning that associated risks may outweigh benefits, according to UK media reports.

Thank you for reading this post, don't forget to subscribe!

UK regulators are set to decide on the approval of lecanemab, approved in the US last year, and donanemab, awaiting approval, next week. These drugs, designed to slow cognitive decline by clearing amyloid protein, have been linked to brain shrinkage and side effects classified as “amyloid-related imaging abnormalities” (ARIA), including brain swelling and bleeding in up to one-third of patients.

Severe side effects, including fatalities, have been reported in approximately 1% of patients. Lecanemab has a “black-box warning” indicating potential serious adverse events, according to the US Food and Drug Administration.

Professor Rob Howard from the University College of London Institute of Mental Health likened ARIA-related MRI scans to those of patients with strokes or traumatic brain injuries. Imaging data reveals patients receiving the drugs may lose brain volume.

Dr. Madhav Thambisetty from the US National Institute on Aging reported brain volume loss of up to three teaspoons in patients receiving the largest dose. Despite manufacturers claiming a 27% (lecanemab) and 35% (donanemab) potential decline in cognitive decline compared to a placebo, the improvement on the Alzheimer’s symptom assessment scale is minimal.

Brain shrinkage, indicative of Alzheimer’s, raises questions about the effectiveness of treatments potentially worsening underlying pathology. Some patients with ARIA experienced cognitive deterioration five times that of unmedicated Alzheimer’s patients, and there were cases of severe adverse events, including a patient in the lecanemab trial who died from a 7cm brain hemorrhage.

Aducanumab, another drug hailed as a miracle treatment in 2021, is expected to be discontinued by its manufacturer this year due to brain swelling and bleeding risks revealed in clinical data.


Discover more from Naija247news

Subscribe to get the latest posts to your email.

Emman Tochi
Emman Tochihttps://naija247news.com
Emma Tochi is Naija247news Media Northern Bureau Chief, he's based in FCT Abuja. He overseas the northern operations of this business media

Share post:

Subscribe

Popular

More like this
Related

NSCDC deploys personnel to JAMB CBT centres in Anambra

April 24, 2024. Azonuchechi Chukwu. The Nigeria Security and Civil Defence...

Four Persons Dies In Akwa-Ibom Auto Crash

April 24, 2024. Azonuchechi Chukwu. Four friends have died in an...

Kidnappers and terrorists should be properly punished for their crimes – Murdered Professor says in last interview

April 24, 2024. Azonuchechi Chukwu. Professor of Human Rights and Gender...

Family of Late Sound Engineer Have Refused to Exhume His Body – Producer says

April 24, 2024. Azonuchechi Chukwu. Movie Producer, Stanely Ontop says the...

Discover more from Naija247news

Subscribe now to keep reading and get access to the full archive.

Continue reading